Active Ingredient History
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adrenocortical Carcinoma (Phase 1)
Appendix (Phase 1)
Arthritis, Psoriatic (Phase 3)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 4)
Breast Carcinoma In Situ (Phase 2)
Breast Diseases (Phase 2)
Breast Neoplasms, Male (Phase 3)
Carcinoma (Phase 2)
Carcinoma, Adenoid Cystic (Phase 1)
Carcinoma, Ductal, Breast (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Islet Cell (Phase 1)
Carcinoma, Mucoepidermoid (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Cardiotoxicity (Phase 3)
Central Nervous System Diseases (Phase 1/Phase 2)
Chemotherapy-Induced Febrile Neutropenia (Phase 3)
Cholangiocarcinoma (Phase 2)
Cognition Disorders (Phase 1/Phase 2)
Colonic Neoplasms (Phase 3)
Colorectal Neoplasms (Phase 3)
Depression (Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy, Combination (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 2/Phase 3)
Ependymoma (Phase 1)
Epidermal Growth Factor (Phase 2)
ErbB Receptors (Phase 2)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 2)
Fallopian Tube Neoplasms (Phase 1)
Gallbladder Neoplasms (Phase 2/Phase 3)
Gastrinoma (Phase 1)
Gastrointestinal Neoplasms (Phase 2)
Genes, erbB-2 (Phase 2)
Glioma (Phase 1/Phase 2)
Glucagonoma (Phase 1)
Hamartoma (Phase 1)
Head and Neck Neoplasms (Phase 2)
Health Services for the Aged (Phase 2)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 2)
Helicobacter pylori (Phase 4)
Hemangiosarcoma (Phase 2)
Hematologic Neoplasms (Phase 1)
Hodgkin Disease (Phase 1)
Hypertrophy, Left Ventricular (Phase 2)
Immunotherapy (Phase 2)
Inflammatory Breast Neoplasms (Phase 3)
Infusions, Intravenous (Phase 4)
Insulinoma (Phase 1)
Intestinal Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Liver Neoplasms (Phase 1)
Lung Neoplasms (Phase 2/Phase 3)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 1/Phase 2)
Meningeal Carcinomatosis (Phase 1/Phase 2)
Meninges (Phase 2)
Menopause (Phase 1)
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Mycosis Fungoides (Phase 1)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 4)
Neoplasms ()
Neoplastic Cells, Circulating (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2/Phase 3)
Oxaliplatin (Phase 2)
Paget Disease, Extramammary (Phase 2)
Pancreatic Neoplasms (Phase 2/Phase 3)
Peritoneal Neoplasms (Phase 1)
Pharmacokinetics (Phase 2)
Pleural Effusion, Malignant (Phase 1)
Postmenopause (Phase 1/Phase 2)
Progression-Free Survival (Phase 2)
Prostatic Neoplasms (Phase 2/Phase 3)
Psoriasis (Phase 3)
Radiotherapy (Phase 2)
Rectal Neoplasms (Phase 2)
Rocky Mountain Spotted Fever (Phase 3)
Salivary Gland Neoplasms (Phase 2/Phase 3)
Sarcoma (Phase 2)
Skin Neoplasms (Phase 2/Phase 3)
Small Cell Lung Carcinoma (Phase 2)
Somatostatinoma (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 4)
Testicular Neoplasms (Phase 1)
Thyroid Carcinoma, Anaplastic (Phase 1)
Thyroid Neoplasms (Phase 1)
Treatment Outcome (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2/Phase 3)
Urological Manifestations (Early Phase 1)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2/Phase 3)
Vaginal Neoplasms (Phase 1)
Vipoma (Phase 1)
Vulvar Neoplasms (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
